References
- Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15(12): 712–29.
- Sudhan DR, Siemann DW. Cathepsin L targeting in cancer treatment. Pharmacol Ther. 2015;155:105–16.
- Ganguly SS, Plattner R. Activation of Abl family kinases in solid tumors. Genes Cancer. 2012;3(5-6):414–25.
- Fiore LS, Ganguly S, Sledziona J, Cibull ML, Wang C, Richards DL, Neltner JM, Beach C, McCorkle JR, Kaetzel DM, et al. c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene. 2014;33(36):4508–20.
- Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Thacker MA, et al. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene. 2012;31(14):1804–16.
- Jain A, Tripathi R, Turpin CP, Wang C, Plattner R. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Oncogene. 2017;36(32):4585–96.
- Tripathi R, Fiore LS, Richards DL, Yang Y, Liu J, Wang C, Plattner R. Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis. Sci Signal. 2018;11(518).
- Dittmer J. The role of the transcription factor Ets1 in carcinoma. Semin Cancer Biol. 2015;35:20–38.
- Murtas D, Piras F, Minerba L, Ugalde J, Piga M, Maxia C, Perra MT, Sirigu P. Nuclear factor-kappaB expression is predictive of overall survival in patients with cutaneous melanoma. Oncol Lett. 2010; 1(4): 633–9.
- Vizcaino C, Mansilla S, Portugal J. Sp1 transcription factor: A long-standing target in cancer chemotherapy. Pharmacol Ther. 2015;152:111–24.